Carolinas Wealth Consulting’s Charles River Laboratories CRL Stock Holding History

Carolinas Wealth Consulting’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7	Closed	-$1.05K	–	191
2025 Q1	$1.05K	Buy	7 +6	+600%	+$1.01K	﹤0.01%	900
2024 Q4	$185	Buy	+1	New	+$193	﹤0.01%	1048
2024 Q3	–	Sell	-1	Closed	-$207	–	1060
2024 Q2	$207	Buy	+1	New	+$227	﹤0.01%	1028
2023 Q4	–	Sell	-36	Closed	-$6.06K	–	1005
2023 Q3	$6.06K	Hold	36	–	–	﹤0.01%	585
2023 Q2	$7.57K	Hold	36	–	–	﹤0.01%	629
2023 Q1	$7.27K	Sell	36 -10	-22%	-$2.27K	﹤0.01%	648
2022 Q4	$10K	Hold	46	–	–	﹤0.01%	624
2022 Q3	$9K	Buy	+46	New	+$9.93K	﹤0.01%	576
2022 Q2	–	Sell	-32	Closed	-$9K	–	895
2022 Q1	$9K	Buy	32 +8	+33%	+$2.47K	﹤0.01%	614
2021 Q4	$9K	Buy	+24	New	+$9.32K	﹤0.01%	623

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Carolinas Wealth Consulting's CRL Position: Q2 2025 in Review

Carolinas Wealth Consulting sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 7 shares — an estimated $1.05K sold.

Carolinas Wealth Consulting first reported a position in CRL in Q4 2021 and held it in 10 quarters. The position peaked at $10K in Q4 2022. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

Carolinas Wealth Consulting reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
Carolinas Wealth Consulting sold 7 Charles River Laboratories shares in Q2 2025, an estimated $1.05K.
Carolinas Wealth Consulting first reported a position in Charles River Laboratories in Q4 2021 and held it in 10 quarters.
Carolinas Wealth Consulting's Charles River Laboratories position peaked at $10K in Q4 2022.
519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2025.